Howard Brown HealthChicago, Illinois, United States
Disclosure(s): Gilead Sciences, Inc.: Speaker; Theratechnologies: Speaker; ViiV: Speaker
155 - Long-Acting Subcutaneous Lenacapavir in People with Multi-Drug Resistant HIV-1: 3-Year Results of the CAPELLA Study
Thursday, October 17, 20242:00 PM – 2:15 PM US PT